Effects of Baloxavir Marboxil Plus Neuraminidase Inhibitor vs Neuraminidase Inhibitor in High-risk Patients Hospitalized With Severe Influenza: A Post Hoc Analysis of the Flagstone Trial - Takeaways - MDSpire

Effects of Baloxavir Marboxil Plus Neuraminidase Inhibitor vs Neuraminidase Inhibitor in High-risk Patients Hospitalized With Severe Influenza: A Post Hoc Analysis of the Flagstone Trial

  • By

  • Mengwei Yan

  • Xiaoying Gu

  • Yeming Wang

  • Bin Cao

  • July 25, 2025

  • 0 min

Share

  • 1

    Combining baloxavir with neuraminidase inhibitors did not show significant benefits in severe influenza compared to neuraminidase inhibitors alone.

  • 2

    In patients infected with influenza A H3N2, the combination treatment resulted in a significantly shorter time to clinical improvement.

  • 3

    The dual antiviral group had a significantly lower mortality rate compared to the mono antiviral group in hospitalized high-risk patients.

  • 4

    The combination therapy was associated with a shorter time to cessation of viral shedding and greater reduction in virus titer.

  • 5

    Serious adverse events were comparable between the dual and mono antiviral groups, indicating safety in combination therapy.

Original Source(s)

Effects of Baloxavir Marboxil Plus Neuraminidase Inhibitor vs Neuraminidase Inhibitor in High-risk Patients Hospitalized With Severe Influenza: A Post Hoc Analysis of the Flagstone Trial

  • by Mengwei Yan, Xiaoying Gu, Yeming Wang, Bin Cao

  • July 25, 2025

Related Content

The lipid–inflammation axis in rosacea: mechanistic insights and therapeutic implications

Mycobacterium abscessus infection in a young man with cystic fibrosis: a case report and literature review

CDC Lists Dozens of Infectious Disease Tests as Unavailable

More than two dozen assays paused or discontinued, with alternative testing options noted